Taylor S H
University Department of Cardiovascular Studies and Medical, Department of Cardiology, General Infirmary, Leeds, United Kingdom.
Am Heart J. 1988 Nov;116(5 Pt 2):1426-34. doi: 10.1016/0002-8703(88)90135-4.
Celiprolol is a third-generation, beta-adrenoceptor antagonist with ancillary pharmacologic properties that are potentially advantageous in the treatment of hypertension. Celiprolol provides 24-hour control of blood pressure and in formal clinical trials has been found superior to a placebo and of equal efficacy to other commonly used beta-blocking drugs. It has also been found to be equally as effective as enalapril in lowering the resting blood pressure and superior in controlling the increases in blood pressure and heart rate during exercise. Celiprolol is known to exert a beneficial effect on the atheroprotective components of the risk factors for coronary heart disease, such as cholesterol triglyceride, and fibrinogen. Therefore the primary attributes of beta-blockade are uniquely advanced by celiprolol's ancillary pharmacologic activities.
塞利洛尔是一种第三代β肾上腺素能受体拮抗剂,具有辅助药理特性,在高血压治疗中可能具有优势。塞利洛尔可实现24小时血压控制,在正式临床试验中已被证明优于安慰剂,且与其他常用β受体阻滞剂疗效相当。还发现它在降低静息血压方面与依那普利同样有效,在控制运动期间血压和心率升高方面更具优势。已知塞利洛尔对冠心病危险因素的动脉粥样硬化保护成分,如胆固醇、甘油三酯和纤维蛋白原,具有有益作用。因此,塞利洛尔的辅助药理活性独特地提升了β受体阻滞的主要特性。